Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study

Bendamustine demonstrated synergistic efficacy with bortezomib against multiple myeloma (MM) cells in vitro and seems an effective treatment for relapsed-refractory MM (rrMM). This phase II study evaluated bendamustine plus bortezomib and dexamethasone (BVD) administered over six 28-day cycles and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Offidani, M, Corvatta, L, Maracci, L, Liberati, A M, Ballanti, S, Attolico, I, Caraffa, P, Alesiani, F, Caravita di Toritto, T, Gentili, S, Tosi, P, Brunori, M, Derudas, D, Ledda, A, Gozzetti, A, Cellini, C, Malerba, L, Mele, A, Andriani, A, Galimberti, S, Mondello, P, Pulini, S, Coppetelli, U, Fraticelli, P, Olivieri, A, Leoni, P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880441/
https://www.ncbi.nlm.nih.gov/pubmed/24270324
http://dx.doi.org/10.1038/bcj.2013.58

Ejemplares similares

Ejemplares similares